Medicamen Biotech has informed that there are no reportable events, information etc., that have a bearing on the operation/performance of the Company including price sensitive information which may result in the increase in the Prices of the shares of the Company under Regulation 30 of SEBI (LODR) Regulations, 2015. The increase in the share price is purely market driven and the current market conditions; the management of the company is in no way connected with such increase in Price of shares. The company also assured that it would always comply with the reporting requirements of the stock exchanges as provided in Regulations 30 of SEBI (LODR) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
